Yılmaz Emsal Pınar Topdağı, Kumtepe Yakup
Clinic of Gynecology and Obstetrics, Nene Hatun Gynecology and Obstetrics Hospital, Erzurum, Turkey.
Department of Gynecology and Obstetrics, Atatürk University School of Medicine, Erzurum, Turkey.
Eurasian J Med. 2016 Oct;48(3):192-198. doi: 10.5152/eurasianjmed.2016.0259.
Currently, no clinically useful tumor marker is available for primary diagnosis in endometrial cancer. Human epididymis protein-4 (HE-4) has high sensitivity and specificity as a tumor marker. Further, HE-4 has been shown to be elevated in early stage endometrial cancer and is more sensitive than CA 125. In our study, CA 125 and HE-4 reputation as a tumor marker for diagnosis of ovarian and endometrial cancer with the use of both the availability and affect the way we investigated the rate of diagnosis.
Here 20 patients with ovarian cancer, 26 patients with endometrial cancer, which had been histologically diagnosed, and 40 healthy volunteers were included. Peripheral blood samples were taken and serum CA 125 and HE-4 were tested.
Serum CA 125 and HE-4 levels in patients with ovarian cancer were found to be significantly higher than those in healthy volunteers (p<0.05). Receiver-operating characteristic (ROC) analysis was performed. For patients with ovarian cancer and healthy controls, the CA 125 (0.83) and HE-4 (0.84) levels showed increased sensitivity (95%). There was no significant difference in the CA 125 levels in patients with endometrial cancer and healthy controls (p>0.05), whereas HE-4 levels were found to be higher in patients with endometrial cancer than in healthy controls (p<0.05). ROC analysis was performed. For endometrial cancer patients and healthy controls, the CA 125 (0.59) and HE-4 (0.63) levels showed increased sensitivity (88.5%).
In ovarian and endometrial cancer, wherein early diagnosis is the most important factor for prognosis and survival, HE-4 is a new serum tumor marker that can be used with the aim of noninvasive diagnoses. For early diagnosis, the concomitant use of CA 125 and HE-4 is more effective and reliable than using either of them alone.
目前，尚无临床上可用的肿瘤标志物用于子宫内膜癌的初步诊断。人附睾蛋白4（HE-4）作为一种肿瘤标志物具有高敏感性和特异性。此外，HE-4已被证明在早期子宫内膜癌中升高，并且比CA 125更敏感。在我们的研究中，利用CA 125和HE-4作为诊断卵巢癌和子宫内膜癌的肿瘤标志物的可用性及其影响方式，我们研究了诊断率。
纳入20例经组织学诊断的卵巢癌患者、26例子宫内膜癌患者以及40名健康志愿者。采集外周血样本并检测血清CA 125和HE-4。
发现卵巢癌患者血清CA 125和HE-4水平显著高于健康志愿者（p<0.05）。进行了受试者操作特征（ROC）分析。对于卵巢癌患者和健康对照，CA 125（0.83）和HE-4（0.84）水平显示出较高的敏感性（95%）。子宫内膜癌患者与健康对照的CA 125水平无显著差异（p>0.05），而子宫内膜癌患者的HE-4水平高于健康对照（p<0.05）。进行了ROC分析。对于子宫内膜癌患者和健康对照，CA 125（0.59）和HE-4（0.63）水平显示出较高的敏感性（88.5%）。
在卵巢癌和子宫内膜癌中，早期诊断是影响预后和生存的最重要因素，HE-4是一种可用于无创诊断的新型血清肿瘤标志物。对于早期诊断，联合使用CA 125和HE-4比单独使用其中任何一种更有效、更可靠。
